Cargando…
Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
INTRODUCTION: Dotinurad is a newer urate-lowering agent that selectively inhibits urate transporter 1 in the renal proximal tubule and increases urinary urate excretion. Currently, little is known about the clinical efficacies of dotinurad in patients with hyperuricemia and hypertension. The aim of...
Autores principales: | Tanaka, Atsushi, Taguchi, Isao, Hisauchi, Itaru, Yoshida, Hisako, Shimabukuro, Michio, Hongo, Hiroshi, Ishikawa, Tetsuya, Kadokami, Toshiaki, Yagi, Shusuke, Sata, Masataka, Node, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351195/ https://www.ncbi.nlm.nih.gov/pubmed/37461063 http://dx.doi.org/10.1186/s40001-023-01208-1 |
Ejemplares similares
-
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
por: Kuriyama, Satoru
Publicado: (2019) -
A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
por: Hosoya, Tatsuo, et al.
Publicado: (2020) -
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
por: Okui, Daisuke, et al.
Publicado: (2019) -
Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
por: Kumagai, Yuji, et al.
Publicado: (2019) -
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
por: Fukase, Hiroyuki, et al.
Publicado: (2019)